YKL-40 expression in soft-tissue sarcomas and atypical lipomatous tumors

Acta Orthopaedica

Volumn 85, Issue 2, 2014, Pages 195-200

  Harving, Mette L ^a   Christensen, Lise H ^a   Ringsholt, Merete ^b   Lausten, Gunnar S ^a   Petersen, Michael M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY COLLEGE COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; PROTEIN YKL 40; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; ATYPICAL LIPOMATOUS TUMOR; CANCER GRADING; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CHILD; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MIDDLE AGED; PRESCHOOL CHILD; PROTEIN EXPRESSION; SCHOOL CHILD; SOFT TISSUE SARCOMA; SURVIVAL RATE; TISSUE MICROARRAY; TUMOR BIOPSY; VERY ELDERLY; YOUNG ADULT;

ADIPOKINES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LECTINS; LIPOMA; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SARCOMA; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84896528775     PISSN: 17453674     EISSN: 17453682     Source Type: Journal    
DOI: 10.3109/17453674.2014.893496     Document Type: Article

References (26)

1. Bi J, Lau S H, Lv Z L, Xie D, Li W, Lai Y R, Zhong J M, Wu H Q, Su Q, He Y L, Zhan W H, Wen J M, Guan X Y. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Human Pathology 2009; 40: 1790-7.
2. Daugaard S, Christensen L H, Høgdall E. Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40. APMIS 2009; 117: 518-28.
3. Dei Tos A P, Pedeutour F. Atypical lipomatous tumour /well differentiated liposarcoma. In: World Health Organisation classification of tumours. Pathology and genetics of tumours of soft tissue and bone (Fletcher CDM, Unni KK, Mertens F, eds). IARCPress, Lyon 2002: 35-7.
4. Dei Tos A P, Pedeutour F. Atypical lipomatous tumour. In: WHO classification of tumours of soft tissue and bone. International agency for research on cancer (Fletcher CDM, Brigde JA, Hogendoom PCW, Mertens F, eds). Lyon 2013: pp. 33-6.
5. Faibish M, Francescone R, Bentley B, Yan W, Shao R. A YKL-40 neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther. 2011; 10 (5): 742-51.
6. Guillou L, Coindre J M, Bonichon F, Nguyen B B, Terrier P, Collin F, Vilain M O, Mandard A M, Le Doussal V, Leroux A, Jacquemier J, Duplay H, Sastre-Garau X, Costa J. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997; 15: 350-62.
7. Gustafson P. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand (suppl 259) 1994: 1-31.
8. Høgdall E V, Ringsholt M, Høgdall C K, Christensen I J, Johansen J S, Kjaer S K, Blaakaer J, Ostenfeld-Møller L, Price P A, Christensen L H. YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer 2009; 9: 8.
9. Johansen J S. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodeling, fibrosis and cancer. Dan Med Bull 2006; 53: 172-209.
10. Johansen J S, Høyer P E, Larsen L A, Price P A, Møllgård K. YKL-40 protein expression in the early developing human musculoskeletal system. J Histochem Cytochem 2007; 55: 1213-28.
11. Johansen J S, Lottenburger T, Nielsen H J, Jensen J E, Svendsen M N, Kollerup G, Christensen I J. Diurnal, weekly and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol Biomarkers Prev 2008; 17: 2603-8.
12. Johansen J S, Schultz N A, Jensen B V. Plasma YKL-40: a potential new cancer biomarker? Future Oncol 2009; 5: 1065 82.
13. Lee C G, Hartl D, Lee G R, Koller B, Matsuura H, Da Silva C A, Sohn M H, Cohn L, Homer R J, Kozhich A A, Humbles A, Kearley J, Coyle A, Chupp G, Reed J, Flavell R A, Elias J A. Role of breast regression protein 39 (BRP-39)/Chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 2009; 206: 1149-66.
14. Lee C G, Da Silva C A, Dela Cruz C S, Ahangari F, Ma B, Kang M J, He C H, Takyar S, Elias J A. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol 2011; 73: 479-501
15. Levine E A. Prognostic factors in soft tissue sarcoma. Semin Surg Oncol 1999; 17: 23-32.
16. Pelloski C E, Mahajan A, Maor M, Chang E L, Woo S, Gilbert M, Colman H, Yang H, Ledoux A, Blair H, Passe S, Jenkins R B, Aldape K D. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 2005; 1: 3326-34.
17. Ramanathan R C, A'Hem R, Fisher C, Thomas J M. Prognostic Index for Extremity Soft Tissue Sarcomas With Isolated Local Recurrence. Ann Surg Oncol 2001; 8: 278-89.
18. Rehli M, Krause S W, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997; 43: 221-5
19. Ringsholt M, Høgdall E V, Johansen J S, Price P A, Christensen L H. YKL-40 protein expression in normal adult human tissues-an immunohistochemical study. J Mol Histol 2007; 38: 33-43.
20. Roslind A, Knoop A S, Jensen M, Johansen J S, Nielsen D L, Price P A, Balslev E. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer. Breast Cancer Res Treat 2008; 112: 275-85.
21. Rydholm A, Gustafson P. Should tumor depth be included in prognostication of soft tissue sarcoma? BMC Cancer 2003; 3: 17.
22. Schmidt H, Johansen J S, Gehl J, Geertsen P F, Fode K, von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with Mmetastatic melanoma. Cancer 2006; 106: 1130-9.
23. Shao R, Hamel K, Petersen L, Cao Q J, Arenas R B, Bigelow C, Bentley B, Yan W. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 2009; 28: 4456-68.
24. Singer S, Corson J M, Gonin R, Labow B, Eberlein T J. Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg 1994; 219: 165-73.
25. Trojani M, Contesso G, Coindre J M, Rouesse J, Bui N B, de Mascarel A, Goussot J F, David M, Bonichon F, Lagarde C. Soft tissue sarcoma of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984; 33: 37-42.
26. Yang G F, Cai P Y, Li X M, Deng H X, He W P, Xie D. Expression and clinical significance of YKL-40 protein in epithelial ovarian cancer tissues. Chinese J Cancer 2009; 28: 142-5.